Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Depression
Major Depressive Disorder

Interventions

DRUG: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer